The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | LINKER-MM1 longer follow-up: linvoseltamab in patients with R/R multiple myeloma
In this video, Mansi Shah, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, shares longer follow-up results from the LINKER-MM1 study (NCT03761108), which is evaluating linvoseltamab, an anti-BCMAxCD3 bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Shah highlights impressive findings in a heavily pre-treated patient population, reporting an overall response rate of approximately 70% and a complete response rate of over 50%. Dr Shah emphasizes the need for vigilance in managing infections – an important side effect of this class of bispecific antibodies – to improve patient outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
